Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
17.52
+0.66 (3.91%)
At close: Aug 13, 2025, 4:00 PM
17.57
+0.05 (0.29%)
After-hours: Aug 13, 2025, 6:43 PM EDT
Beam Therapeutics Employees
Beam Therapeutics had 483 employees as of December 31, 2024. The number of employees increased by 47 or 10.78% compared to the previous year.
Employees
483
Change (1Y)
47
Growth (1Y)
10.78%
Revenue / Employee
$124,787
Profits / Employee
-$825,224
Market Cap
1.72B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BEAM News
- 8 days ago - Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 7 weeks ago - Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases - Seeking Alpha
- 2 months ago - Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress - GlobeNewsWire
- 2 months ago - Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease - GlobeNewsWire
- 2 months ago - Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 3 months ago - Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress - GlobeNewsWire
- 3 months ago - Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire